Stock Ratings / Health Care / ANGO / earnings

RCEL (44) SENS (38) SGHT (38) DCTH (57) ⌘ Pro Terminal →

AngioDynamics Inc. (ANGO) Next Earnings Date & Expected ±12.5% Move

$12.35 +1.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.37

AngioDynamics Inc. (ANGO) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $519.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.37 (+0.14%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANGO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY ANGO SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (26% of score)

FRED Regime × Technicals: 43% of 52W Range • RSI-14 at 39.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$11.52-2.4% Next Q

Q2 (-2Q)

Grade D$11.24+10.1% Next Q

Q3 (-1Q)

Grade D$12.37-0.2% Next Q

Current

Grade D$12.35-1.4% Hist 90D α

Trajectory: D (42) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ANGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ANGO currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.18) and Max Pain ($12.97) forces dealer call-delta covering toward $17.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ANGO Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

NEXT EST. WINDOW: Nov 29, 2026 (~27 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.54 Expected Swing

MODEL EARNINGS SETUP GAUGE

ANGO Quantitative Pre-Earnings Setup: 50/100

Trailing EPS: $4.25 • YoY Revenue Growth: 9.5%

Model Bullish Setup (50/100)Model Risk Weight (50/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2026-05-31	$320.2M	-$36.7M	$508.0K	54.6%
FY 2024	2025-05-31	$292.5M	-$34.0M	-$14.6M	53.9%
FY 2023	2024-05-31	$303.9M	-$184.3M	-$28.2M	54.6%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANGO)

✓Walkthrough of ANGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.89%📐 HORIZONTAL RANGE

2026-10-30O $12.32H $12.35L $11.89C $12.35VOL 475.8K

RES: $17.68SUP: $10.46SMA50: $14.18SMA200: $12.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANGO Butterfly Map → + Track ANGO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +9.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANGO)

Health Care Rank #344 of 1016 ⚔️ RCEL vs ANGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANGO vs. RCEL, SENS, SGHT, DCTH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AngioDynamics Inc. (ANGO) ranks #344 by composite RQD confidence (50/100, grade D) and #441 by equity capitalization ($519.4M). Within this direct 5-issuer industry benchmark cohort, ANGO leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with ANGO at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANGO ACTIVE AngioDynamics Inc.	D	50/100	—	54.6%	-23.4%	+1.81%	$519.4M	Benchmark Subject
RCEL Avita Medical Inc.	D	44/100	—	82.1%	-35.0%	+1.27%	$516.8M	/rcel-vs-ango →
SENS Senseonics Holdings Inc.	D-	38/100	—	44.7%	-35.0%	+4.39%	$515.5M	/sens-vs-ango →
SGHT Sight Sciences Inc.	D-	38/100	—	86.2%	-35.0%	+3.57%	$527.2M	/sght-vs-ango →
DCTH Delcath Systems Inc.	D+	57/100	—	86.2%	0.8%	-1.48%	$508.0M	/dcth-vs-ango →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0001275187

In its most recent audited fiscal period (FY2025, filed 2026-05-31), AngioDynamics Inc. (ANGO) reported GAAP revenue of $320.2M (+9.5% vs. FY2024 revenue of $292.5M , and +5.4% cumulative change since FY2023) , GAAP net income of -$36.7M, operating cash flow of $3.1M, and free cash flow of $508.0K (+103.5% YoY). On the balance sheet, ANGO closed FY2025 with $269.7M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-05-31	$320.2M	-$36.7M	$3.1M	$508.0K	$269.7M	—
FY2024 (FY)	2025-05-31	$292.5M	-$34.0M	-$10.1M	-$14.6M	$291.6M	—
FY2023 (FY)	2024-05-31	$303.9M	-$184.3M	-$28.2M	-$28.2M	—	—

3. ANGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, AngioDynamics Inc. (NASDAQ: ANGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $12.35 (+1.81% 1D, market cap $519.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANGO ranks #344 in composite RQD confidence.

How does ANGO compare to RCEL and SENS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, RCEL (Avita Medical Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $516.8M) and SENS (Senseonics Holdings Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $515.5M). Among the 5-stock peer group, ANGO leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANGO?

Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANGO trading relative to its 50-day, 200-day, and 52-week technical levels?

ANGO last traded at $12.35 (+1.81% on volume of 476,210 shares), positioning the stock -12.91% below its 50-day simple moving average ($14.18) and -1.04% below its 200-day simple moving average ($12.48). Across its 52-week range of $9.39 to $16.29, ANGO sits at the 42.9% percentile with a 14-day RSI of 39.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.81 to $13.89).

ANGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ANGO's next earnings date?

Based on SEC filing cadence, AngioDynamics Inc. (ANGO)'s next quarterly reporting window is estimated around Nov 29, 2026.

How much is ANGO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ANGO, spanning a range between $10.81 and $13.89.

Direct Sub-Reports: ANGO RQD Cockpit ANGO 12M Forecast ANGO Earnings & Move ANGO Dividends & DRIP ANGO Insiders & 13F ANGO Whale Options ANGO Profit Sankey ANGO News & Why